Related Experiment Video
Updated: Apr 20, 2026

04:02
Author Spotlight: Developing Precise and Clinically Relevant Models for Studying Secondary Degeneration in Traumatic Optic Neuropathy
Published on: November 29, 2024
1.6K
The kallikrein system in retinal damage/protection
Tomomi Masuda1, Masamitsu Shimazawa1, Hideaki Hara1
1Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
European Journal of Pharmacology
|December 3, 2014
Summary
Tissue kallikrein, unlike plasma kallikrein, protects against eye diseases by normalizing retinal permeability and inhibiting neovascularization. Its mechanism involves cleaving vascular endothelial growth factor (VEGF).
Area of Science:
- Biochemistry
- Ophthalmology
- Protease Function
Background:
- Kallikrein is a serine protease within the kallikrein-kinnin system.
- Kallikrein, sourced from plasma or tissue, impacts various eye conditions.
- Plasma kallikrein exacerbates retinal vascular permeability and intraocular hemorrhage.
Purpose of the Study:
- To investigate the contrasting roles of plasma and tissue kallikrein in ocular diseases.
- To elucidate the protective mechanisms of tissue kallikrein in the eye.
- To explore the therapeutic potential of tissue kallikrein for VEGF-related eye diseases.
Main Methods:
- Comparative analysis of plasma and tissue kallikrein activities.
- Assessment of retinal vascular permeability and neovascularization.
- Investigation of kallikrein's interaction with vascular endothelial growth factor (VEGF).
Main Results:
- Tissue kallikrein normalizes retinal vasopermeability.
- Tissue kallikrein inhibits retinal neovascularization and ischemic injury.
- Tissue kallikrein's protective effect is linked to vascular endothelial growth factor (VEGF) cleavage.
Conclusions:
- Tissue kallikrein demonstrates protective effects in ocular conditions, contrasting with plasma kallikrein.
- The cleavage of VEGF by tissue kallikrein is a key protective mechanism.
- Tissue kallikrein holds potential for treating eye diseases associated with VEGF production.

